Abstract
Intrathecal (i.t.) administration of morphine (1, 3 or 10 micrograms) effectively inhibited the passage of a radiolabeled marker through the gastrointestinal tract of mice. This effect was reversed by pretreatment with naloxone (2 mg/kg s.c.). Transection of the spinal cord at the level of the second thoracic vertebra (T2) slowed control transit when measured after 4 hr; nevertheless, i.t. morphine inhibited transit in these paralyzed animals. Similarly, i.c.v. administration of morphine (1, 3 or 10 micrograms) inhibited transit regardless of whether the spinal cord was transected at T2. Lower efficacy was seen with i.p. (10-300 micrograms/kg) or i.v. (10 micrograms) morphine than with comparable doses given i.t. (10 micrograms). Intrathecal administration (1, 3 or 10 micrograms) of the proposed selective delta opioid agonist peptides, D-Ala2-D-Leu5-enkephalin, D-Pen2-L-Cys5-enkephalin or i.t. administration of D-Ser2-Leu-enkephalin-(Thr6) (10 micrograms) were effective in inhibiting gastrointestinal transit. In contrast, the proposed kappa agonists, ketocyclazocine (1, 3 or 10 micrograms) or dynorphin-(1-13) (1, 10 or 100 micrograms), did not affect transit after i.t. administration. Dynorphin-(1-13) (10, 30 or 100 micrograms) or dynorphin-(1-9) (10, 30 or 100 micrograms) similarly did not affect transit after i.c.v. administration. Whereas D-Ala2-D-Leu5-enkephalin (1, 3 or 10 micrograms) and D-Ser2-Leu-enkephalin-(Thr6) (10 micrograms) were also efficacious in inhibiting transit by the i.c.v. route, the more delta selective D-Pen2-L-Cys5-enkephalin (1, 3, 10 or 20 micrograms) was not.(ABSTRACT TRUNCATED AT 250 WORDS)
JPET articles become freely available 12 months after publication, and remain freely available for 5 years.Non-open access articles that fall outside this five year window are available only to institutional subscribers and current ASPET members, or through the article purchase feature at the bottom of the page.
|